EnVivo is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders, currently focusing on Alzheimer’s disease, and Schizophrenia. The company’s lead programs include a Nicotinic Alpha 7 Acetylcholine Receptor Agonist Program for cognitive enhancement in Alzheimer’s disease and Schizophrenia, a Histone Deacetylase (HDAC) Inhibitor Program for cognitive enhancement in Alzheimer’s disease, a Gamma Secretase Modulator (GSM) Program for disease modifying treatment of Alzheimer’s disease and a Phosphodiesterase-10 (PDE10) Program for Schizophrenia.